To investigate whether Chinese non-small-cell lung cancer (NSCLC) patients with risk of radiation pneumonitis (RP) (grade ≥ 3) caused by radiotherapy display reliable single-nucleotide polymorphism (SNP) marker(s) located on the transforming growth factor-beta-1 (TGFβ1) gene. Methods: DNA was isolated from blood samples obtained from NSCLC patients (n = 167) treated with radiotherapy alone (n = 23) or chemoradiation (n = 144) with the median total radiation dose of 56 Gy between 2007 and 2010. A comprehensive approach toward characterizing the TGFβ1 SNPs in Chinese patients was carried out in this study. Eight SNPs of the TGFβ1 gene (rs1800469, rs1800471, rs1982073, rs4803455, rs11466345, rs12983047, rs10417924, and rs10980942) were finally genotyped by the direct DNA sequencing method. Kaplan-Meier cumulative probability was used to assess the risk of RP of grade 3 or higher. Cox proportional hazard analysis was used to evaluate the effect of TGFβ1 genotypes on RP risk. Results: A total of 46 patients (27.5%) developed RP of grade 3 or higher, based on Common Terminology Criteria for Adverse Events version 3.0, with a median follow-up of 29.5 months (range, 16-58). The rs1982073 SNP, associated with RP risk in whites, was not found to be associated with the risk of RP of grade 3 or higher in Chinese NSCLC patients. Multivariate analysis found AG/GG genotypes of the novel TGFβ1 SNP rs11466345 to be associated with a significantly higher risk of RP of grade 3 or higher compared with the AA genotypes, after adjustment for age, smoking status, and dosimetric parameters (for mean lung dose, adjusted hazards ratio = 2.295, 95% confidence interval: 1.101-4.783, p = 0.027; for volume of normal lung receiving 20 GY or more radiation, adjusted hazards ratio = 2.142, 95% confidence interval: 1.033-4.441, p = 0.041).
L ung cancer is one of the most common cancers worldwide.
Radiotherapy plays an important role in the treatment of lung cancer. Unfortunately, pulmonary injury after thoracic irradiation (RT) is fairly common. Radiation pneumonitis (RP) is one of the most common dose-limiting toxicities in lung cancer patients receiving radiotherapy. RP usually occurs within 1 to 6 months after completion of radiation therapy, 1 but it can occur as late as 14 months after radiation in some patients. 2 Current population-based pneumonitis risk assessment relies on factors that are related to the patient characteristics, including age; sex, race, smoking [3] [4] [5] ; comorbidities such as impaired vascularity, chronic obstructive pulmonary disease, preexisting fibrotic diseases; or treatment, including chemotherapy, total radiation dose, the dose per fraction, and radiation dosimetric factors. 2, [6] [7] [8] [9] Many studies have confirmed that dose and volume of radiation delivery, measured by mean lung dose (MLD) 1, 6, 7 and relative volume of lung receiving more than a threshold dose (Vdose), 2,6-9 are associated with the risk of RP. However, only a percentage of patients in whom normal lung tissue is exposed to a certain dose and volume of irradiation develop RP, 10 suggesting that patient genetic makeup may play a critical role in individual's response to radiotherapy and RP development.
Several recent studies have investigated plasma levels of transforming growth factor-beta-1 (TGFβ1) as a predictor for RT-induced lung injury. 11, 12 However, these results on the value of TGFβ1 changes in plasma for predicting RP risk are inconsistent [13] [14] [15] partly because TGFβ1 can be produced by both tumor and normal tissues. Other factors, including improper handling of blood samples or inadequate centrifugation conditions, can also falsely increase the calculated level of circulating TGFβ1, 16 which seriously limits this approach for risk prediction.
Recently, several studies have addressed a possible correlation between single-nucleotide polymorphisms (SNPs) in the TGFβ1 gene and RT-induced pneumonitis in cohorts of non-small-cell lung cancer (NSCLC) patients. However, these studies found different results in different populations. 17, 18 Thus, it must be concluded that we are still far from a complete understanding of the genetic basis of variability in normal tissue reactions when lung cancer patients undergo radiotherapy. The goal of this study was a comprehensive investigation of TGFβ1 gene variants to explain the wide range of radiosensitivity observed in Chinese NSCLC patients treated with radiotherapy, to better personalize radiotherapy for these patients.
PATIENTS AND METHODS

Patient Population and Treating Planning
All patients were of Han Chinese ethnicity (CHB). One hundred and sixty-seven patient DNA samples were identified from a database of 323 NSCLC patients treated with definitive radiation at Shanghai Chest Hospital affiliated to Shanghai Jiaotong University between January 2007 and July 2010. Patients with a baseline PaO 2 value less than 80 mmHg were excluded from this database. Patients were staged according to the new staging system initiated by the International Association for the Study of Lung Cancer in 2009. 19 A treatment-planning computed tomography (CT) scan was performed, using intravenous contrast if the patient was not allergic to contrast agent. CT scans with slices 5-mm thick were obtained from the mandible to the lower edge of the liver. Lung dose-volume histograms were computed from the threedimensional dose distributions. Dosimetric data, including MLD, volume of normal lung receiving 5 Gy or more radiation (V5), and volume of normal lung receiving 20 Gy or more radiation (V20), were available for all 167 patients. The median total radiation dose was 56 Gy once daily, receiving 1.8 to 2.0 Gy per fraction to 54 to 60 Gy in 30 fractions over 6 weeks using a 6-MV photon linear accelerator; 15 patients (15 of 167, 9.0%) were treated with stereotactic body radiation therapy using 6 to 7 Gy/fraction per day to 60 to 70 Gy/10 fractions.
Tagging SNP Selection and Genotyping
The TGFβ1 gene, located on chromosome 19, was surveyed for variation from 20 kb upstream to 10 kb downstream of the coding region. HapMap SNP phase II data were used to determine the frequency of SNPs among Han Chinese, and SNP selection was done using the Haploview program with a minor allele frequency (MAF) of more than 0.05 in a Chinese population. In the end, five SNPs (rs4803455, rs11466345, rs12983047, rs10417924, and rs12980942) with MAF more than 5% and three SNPs (rs1800469, rs1982073, and rs1800471) reported in the related literature 17, 18 were selected. A total of eight SNPs across the TGFβ1 gene were considered, including one (rs1800469) in the 5´ flanking region (promoter untranslated region), two (rs1982073 and rs1800471) in the exon regions, two (rs4803455 and rs11466345) in the intronic regions, and three (rs12983047, rs10417924, and rs12980942) in the 3´ flanking region, according to the University of California Santa Cruz database (http://genome.ucsc.edu/) ( Table 1 ).
Blood samples were collected from all study participants. DNA was purified from blood leukocytes using QIAamp 96 DNA Blood Kits (Qiagen, Shanghai, China). The eight TGFβ1 polymorphisms were genotyped by the direct DNA sequencing method. The sequences of polymerase chain reaction primers and annealing temperature are reported in Table 1 . Genotyping was performed by laboratory personnel blinded to sample status, and a random 25% of the samples were genotyped with 100% agreement for all. Two authors independently reviewed the genotyping results, data entry, and statistical analyses.
Follow-Up
Patients were evaluated by radiation oncologists weekly during radiation, 3 to 4 weeks after completion of treatment, and every 2 months during the first 2 years. A chest CT scan was performed at each follow-up evaluation after completion of radiotherapy. If patients had symptoms such as fever, cough, or shortness of breath, they were required to have an immediate examination or intervention, including oral or intravenous steroids, oxygen, and antibiotics. A diagnosis of RP was made with consensus by at least two of three radiation oncologists based on clinical symptoms, with or without radiographic infiltrate changes.
Endpoints and Statistical Analysis
Endpoints (development of grade ≥ 2 or grade ≥ 3 RP) were assessed and graded according to Common Terminology Criteria for Adverse Events version 3.0 ( Table 2 ). 20 The times to endpoints were calculated from radiotherapy start; patients not reaching the endpoint were censored at the last follow-up. The last follow-up date was November 1, 2011. The median follow-up time for all patients was 29.5 months (range, .
Patients were grouped according to their genotypes. Allelic differentiation estimation was undertaken using the SHEsis software (http://www.nhgg.org/analysis). 21 Statistical analysis was performed using SPSS 15.0 statistical software (SPSS Inc., Chicago, IL). Multivariate Cox proportional hazards analysis was performed to calculate the hazard ratio (HR) and confidence interval (CI) to evaluate the influence of genotypes on RP risk adjusting for other covariates (p < 0.10 in the univariate proportional hazard analyses). Kaplan-Meier analysis was performed to estimate the cumulative RP probability. A p value of 0.05 or less was considered statistically significant.
RESULTS
Patient Characteristics and Risk of Radiation Pneumonitis
The patient, tumor, and treatment characteristics are shown in Table 3 . There were 125 men and 42 women, with a median age of 58 years (range, 33-82). Among them, 74.3% (124 of 167) had stage III disease, 32.9% (55 of 167) were never smokers. A total of 23 patients (13.8%) received radiation alone, 144 patients (86.2%) received combined platinum-based chemoradiation, including 102 patients (61.1%) receiving sequential chemoradiation and 42 (25.1%) with concurrent chemoradiation. Of all patients, 91.0% (152 of 167) received median radiation dose of 56 Gy (range, 54-60) with once a day (1.8-2.0 Gy/fraction), and 9.0% (15 of 167) were treated with stereotactic body radiation therapy using 6 to 7 Gy/fraction per day to 60 to 70 Gy/10 fractions. The median values for MLD, V20, and V5 were 9.3 Gy, 17%, and 30%, respectively. Thus for this study 10 Gy, 17%, and 30% were used as cutoff points for MLD, V20, and V5, respectively, to define patient subgroups for further analysis. Of all 167 patients, 46 (27.5%) developed RP of grade 3 or higher; 53 (31.7%) developed grade 2 RP; and 68 (40.7%) grade 1 or lower. RP of grade3 or higher occurred at a median time of 2.54 ± 1.27 months (range, 0.63-4.87) after commencement of radiation treatment. Table 4 shows the associations between RP of grade 3 or higher with patient-, tumor-, and therapy-related characteristics, based on univariate analysis. The result showed that smoking status was marginally related with RP risk (p = 0.061). Radiation dosimetric factors (MLD and V20) were strongly associated with RP risk. Patients with MLD more than 10 Gy had a higher RP risk compared with those with MLD of 10 Gy or lower (HR = 2.411, 95%CI 1.206-4.820, p = 0.013), the same risk differences were found when using the V20 measure (HR = 2.189, 95%CI 1.089-4.399, p = 0.028).
Radiation Pneumonitis and TGFβ1
SNPs and Genotypes Table 5 shows genotype distributions and lists univariate proportional hazard analyses of grade 3 or higher RP in patients with different TGFβ1 genotypes. One SNP, rs11466345, showed significant allelic differentiations with RP of grade 3 risk (HR = 2.088, 95%CI 1.258-3.465, p = 0.004, Table 5 ). Univariate proportional hazard analyses for all eight SNPs showed that AG/GG rs11466345 genotypes were associated with an increased risk of RP of grade 3 or higher (HR = 2.264, 95%CI 1.126-4.552, p = 0.022, Table 5 ). For rs11466345, RP of grade 3 or higher developed in 19.8% (17 of 86) of patients having AA genotype, whereas it developed in 35.8% (29 of 81) of patients having AG/GG genotypes after initiation of radiotherapy. However, none of the three TGFβ1 SNPs (rs1800469, rs1982073, or rs1800471) reported in Western patients 17 were validated to be associated with RP risk (p = 0.663 for rs1800469 and p = 0.632 for rs1982073, Table 5 ) in our studied Chinese patients. In addition, the rs1800471 SNP genotype was GG in 99.4% of the patients (166 of 167), CG in 0.6% of the patients (1 of 167), and CC in 0% of the patients (0 of 167), and thus was not polymorphic in our Chinese patient population.
To further control confounding effects, rs11466345 genotypes in patients with RP of grade 3 or higher were calculated by multivariate analysis with adjustment for the other factors, including age, smoking status, and radiation dosimetric factors, for which p values for RP risk were less than 0.10 in the univariate proportional hazard analyses (Table 6 ). Because V20 and MLD were significantly correlated with each other (r = 0.941; p < 0.001), we only used one of the two as the dosimetric factor. The association between AG/GG rs11466345 genotypes and grade 3 or higher RP risk was virtually unchanged after adjusting by age, smoking status, and MLD in the multivariate analysis (adjusted HR = 2.295, 95% CI 1.101-4.783, p = 0.027). A similar result was obtained when multivariate analysis was adjusted for the other dosimetric factor, V20 (adjusted HR = 2.142, 95% CI 1.033-4.441, p = 0.041), suggesting that rs11466345 polymorphism is an independent factor for RP risk. Figure 1A plots the Kaplan-Meier incidence of RP of grade 3 or higher as a function of time for the AG/GG genotype in rs11466345 (p = 0.034). To identify higher-order interactions in the risk of developing RP, we carried out a classification analysis according to genotype and dosimetric factor (MLD or V20). Patients with AA genotypes in rs11466345, who received MLD of 10 Gy or lesser had the lowest RP incidence in the entire studied group (p = 0.028; Fig. 1B) . The same results were obtained when using the V20 factor. Patients with AG/GG genotypes in rs11466345, who received V20 more than 17% of their normal lung volume had the highest RP risk of the entire studied group (p = 0.036, Fig. 1C ). The association of RP risk with AG/GG rs11466345 genotypes was consistent across different subgroups, both in the patients who received MLD more than 10 Gy or V20 more than 17%, and in the patients receiving 10 Gy MLD or lesser or 17% or lesser V20, suggesting that the genetic predisposition was independent of dosimetric factors.
Association of Genotype and Dosimetric Factor with RP Risk
DISCUSSION
Recently, several studies have analyzed correlations between candidate polymorphisms in the TGFβ1 gene and RT-induced pneumonitis in cohorts of NSCLC patients. 17, 18 However, results have differed worldwide. 17, 18 To study the genetic variants of TGFβ1 associated with RP risk in different populations, we carried out a comprehensive study of genetic variants in the entire gene. In this study, AG/GG genotypes of the novel TGFβ1 SNP rs11466345 were associated with a higher risk of RP in Chinese NSCLC patients treated with radiotherapy. None of the three TGFβ1 SNPs (rs1800469, rs1982073, rs1800471) reported in Western countries, 17 especially rs1982073, were found to be associated with RP risk in our cohort of Chinese patients. TGFβ1 is one of the most extensively studied cytokines in the development of tissue fibrosis in response to irradiation, 22 and TGFβ1 signaling is an important modulator of the inflammatory response. Animal and human studies have demonstrated that TGFβ1 is a major regulator of radiationinduced lung injury 23 as a master switch for development and persistence of fibrosis. 24 Administration of anti-TGFβ antibodies can decrease the inflammatory response and reduce TGFβ activation several weeks after RT, further suggesting that targeting the TGFβ pathway may be a useful strategy to prevent RT-induced lung injury. 25 However, a major concern is that plasma values of TGFβ1, used for predicting RP risk, are inconsistent in the irradiated lung. [13] [14] [15] Excessive platelet degranulation by freezing plasma and long centrifugation is a major problem for the detection of plasma TGFβ1, 26 which seriously limits this approach for risk prediction. 16 Radiogenomics with genotyping analysis of SNPs in TGFβ1 and TGFβ1 pathway genes may allow the identification of genotypes prone to RP. 27, 28 Taking into account different genetic backgrounds in different populations, a comprehensive approach toward characterizing TGFβ1 SNPs in Chinese patients was carried out in our study. We did not use a candidate polymorphism approach, which would have allowed us to focus on potentially functional SNPs reported in the literature, but rather comprehensively covered all SNPs in the entire gene. This Journal of Thoracic Oncology • Volume 7, Number 11, November 2012 TGF β1 gene variants an RP approach would warrant additional investigation of the other tagging SNPs that may have been missed in the previous studies only using the candidate polymorphism method. Because a patient's genome can contain genetic variants in both proinflammatory and anti-inflammatory pathways, this comprehensive approach is much more powerful in detecting the effect of these SNPs on a patient's risk of developing pneumonitis. In our study, TGFβ1 rs11466345 polymorphisms were associated with RP risk in CHB NSCLC patients treated with radiotherapy. Analyzing AG/GG genotypes in rs11466345 with MLD/V20 dosimetric measures seemed to help facilitate stratification of patients into low-, intermediate-, and highrisk groups and further improve predictive power. Our data show that the incidence of RP was lowest in the group with the rs11466345 AA genotype and MLD of 10 Gy or less or V20 of 17% or lower. These findings provide strong support for the novel notion that the rs11466345 polymorphism is associated with RP risk in the CHB population. Because this genetic information can be obtained before the radiation treatment is initiated, this test could be used, in addition to radiation dosimetric factors, as a predictive biomarker to prescribe personalized radiation therapy in Chinese NSCLC patients.
Results of association studies investigating RP and three other SNPs (rs1800469, rs1982073, rs1800471) in different populations, 17, 18 including this study, are summarized in Table 7 . Another Chinese study showed no association between RP risk and three TGFβ1 SNPs (rs1982073, rs1800469, rs1800471) among NSCLC cases treated with radiotherapy, and the same result was confirmed by our study-the only study to date which comprehensively covered all SNPs in the TGFβ1 gene. Association between the rs1982073 polymorphism and RP risk has been commonly observed in white populations, 17 whereas no association was found for Chinese patients, 18 including those in our study. For the rs1800469 SNP, the MAFs for T allele in different populations varied, with reports of 0.288, 0.196, and 0.474 in whites, African Americans, and CHB, respectively, based on HapMap data. In addition, rs1800471 is a common SNP (MAF = 0.070 for C allele) in whites, but was not polymorphic at all in our CHB patients. 18 Different genetic backgrounds between whites and CHB may explain, at least in part, these discrepancies.
Smoking status was marginally related with RP risk in our study (p = 0.064 in the multivariate analysis of MLD, p = 0.079 in the multivariate analysis of V20). Till now, the influence of smoking history on RP risk has been quite unclear. Because MLD and V20 were significantly correlated with each other (r = 0.941; p < 0.001), either MLD or V20 was used in multivariate analyses, but not together. Multivariate analysis was performed with adjustment for the other factors, including age, smoking status, and radiation pneumonitis dosimetric factors (MLD or V20), for which p values for radiation risk were < 0.10 in the univariate proportional hazard analyses. HR, hazard ratio; CI, confidence interval; V20, volume of normal lung receiving 20 GY or more radiation; MLD, mean lung dose. Possible explanations of a decreased inflammatory reaction among smokers include smoking-associated hypoxia; a compromised capacity to repair DNA damage in nonsmoking patients, predisposing them to increased lung toxicity after radiotherapy. 3 Although data from several other studies suggest that nonsmoker is associated with important benefits such as better lung function with regard to diffusing capacity of the lung for carbon monoxide and forced expiratory volume in 1 second. 4, 5 So the smoking role in RP risk is still unclear and controversial. The results should in no way be taken to encourage patient smoking; rather, further investigations on underlying causes for the smoking effect should be undertaken.
There are still several limitations to our study. First, the SNP (rs11466345) associated with risk in our study is intronic, and there is debate regarding the true function of this polymorphism. A recent study 29 demonstrated that the haplotype block in which rs11466345 lies also covers the last two exons and the 3´ untranslated region of the TGFβ1 gene. Thus, it is possible that this SNP is in linkage disequilibrium with a causal SNP, which may either result in a change in amino acid or affect a possible splice variant or the stability of the mRNA, but this is so far unknown. A recent study 29 has reported that SNP rs11466345 (GG) of TGFβ1 was correlated with a statistically significant lower risk of colorectal adenocarcinoma, and a haplotype containing SNP rs11466345 was associated with genetic susceptibility to colorectal neoplasia. Further studies are needed to elucidate the mechanism by which rs11466345 in TGFβ1 affects RP risk in NSCLC patients treated with radiotherapy. FIGURE 1. The effects of single-nucleotide polymorphism at TGFβ 1 rs11466345 and dosimetric parameters on the cumulative incidence of RP of grade 3 or higher. A, Patients with the AG/GG genotypes of TGFβ1 rs11466345 had a statistically significant higher incidence of grade 3 or higher RP compared with AA genotype patients (p = 0.034). B, Patients with the AG/GG genotypes of TGFβ1 rs11466345 and MLD more than 10 Gy had a statistically significant higher incidence of grade 3 or higher RP compared with AA genotype patients (p = 0.028). C, Patients with the AG/GG genotypes of TGFβ1 rs11466345 and V20 higher than 17% had a statistically significant higher incidence of grade 3 or higher RP compared with AA genotype patients (p = 0.036). RP, radiation pneumonitis; TGFβ1, transforming growth factor-beta-1; MLD, mean lung dose; V20, volume of normal lung receiving 20 GY or more radiation.
Second, no baseline pulmonary function analysis was performed in our study. However, patients with a PaO 2 value of less than 80 mmHg, which was independently associated with severe RP more often than a higher PaO 2 value (19% versus 5%, p = 0.034), 30 were excluded from our study. In addition, in several studies, pulmonary function before irradiation was further demonstrated to have no association with the risk of RP, in populations of white, 17 Chinese, 18 and Japanese lung cancer patients. 30 Further follow-up and quantitative analysis of lung function might be needed to ascertain longer tolerance of radiation therapy.
In conclusion, our results suggest that the AG/GG genotypes of novel TGFβ1 SNP rs11466345 were associated with a higher risk of RP in CHB NSCLC patients treated with radiotherapy. Furthermore, rs1982073, associated with RP risk in white patients, was not associated with RP risk in our Chinese patients. This lack of association, which differed markedly from studies of white patients, may suggest the presence of different mechanisms in the pathogenesis of RP among different ethnic groups. Further large-scale studies are required to confirm these findings before polymorphisms can be used as predictive markers to individualize radiation therapy on a genetic basis.
